Susanna Brighenti group - Discovery of pathogenesis in human tuberculosis

Our research aims to study immunopathogenesis in tuberculosis (TB) infection and to explore therapeutic strategies that enhance the ability of the immune system to effectively eradicate Mycobacterium tuberculosis.

The Susanna Brighenti research group at CIM, MedH. Photo: Amalia Kewenter

About our research

We study specific immune responses including the induction and regulation of antimicrobial effector functions in macrophages and T cells, particularly at the local site of Mtb infection. Integration of patient materials with well-defined cell and tissue models in vitro are used to explore pathogenic mechanisms of human TB and associated comorbidities such as HIV and type 2 diabetes.

This translational approach aims to unravel specific cellular and molecular targets relevant for immune reconstitution in vivo. Here, compounds with immunomodulatory properties are used to discover novel host-directed therapies that could enhance immune cell function(s) and support conventional antibiotics in Mtb killing and/or growth control.

The overall purpose of our research is to promote the development of next-generation individualized treatment options for different groups of difficult-to-treat TB patients.

A human macrophage infected with Mtb (red rods in phagosome) is surrounded by T cells. Photo: N/A

Tuberculosis 

Tuberculosis (TB) is caused by Mycobacterium tuberculosis (Mtb) and continues to be one of the world-leading killers among infectious diseases; every second a person in the world is infected with Mtb and every 25 second a person dies from TB. Inadequate use of chemotherapy has resulted in resistance of Mtb to most known antibiotics and increased rates of multidrug-resistant TB (MDR-TB) with low treatment success rates is a growing global threat.

Similar to other serious bacterial infections, effective development of resistance to antibacterial drugs rapidly diminishes the pipeline of drug candidates with efficacy towards Mtb. Host-directed therapies target multiple immune pathways to enhance cure, while reducing disease severity, side effects and problems with drug-resistance. The importance of the immune response in TB control is highlighted by the increased risk of TB in primary immunodeficiencies, HIV infection and upon treatment with TNF-α inhibitors.

Keywords

tuberculosis, infection, immune responses, antimicrobial mechanisms, drug resistance, host-directed therapy, global health

Group leader

Susanna Brighenti

Associate Professor, Group leader
08-585 822 68
H7 Department of Medicine, Huddinge

Susanna Brighenti is Group leader at CIM since 2008.

  • Susanna is Master of Science in Cell biology at Lund University (1997).
  • PhD in Immunology at Active Biotech Research and Lund University (2002).
  • Postdoc in Infection and Immunology at KI (2003-2008).
  • Assistant professor at Karolinska Institutet (2008-2014). 
  • Associate professor in Immunology at Karolinska Institutet (2014).
     

Group members

Marco Loreti

PhD student
H7 Department of Medicine, Huddinge
  • Marco Loreti is Master of Science in Biomedical Sciences at the University of Groningen, the Netherlands (2017).
  • Bachelor of Science in Medical Biotechnology, University of Milan “Statale” (2015).
  • PhD student at Karolinska Institutet from 2019, with his thesis work “Modulation of protective immunity in human tuberculosis”.

Sadaf Kalsum

PhD, Postdoctoral fellow
H7 Department of Medicine, Huddinge

Sadaf Kalsum is Postdoctoral fellow at CIM since March 2020.

  • Sadaf is Master of Science in Medical Biosciences at Linköping University (2009).
  • Research assistant at the Department of Clinical and Experimental Medicine, Linköping University (2011).
  • Laboratory Engineer at the Division of Microbiology, Infection and Inflammation, Linköping University (2013).
  • PhD in Mycobacterium tuberculosis and drug discovery at the Division of Microbiology, infection and Inflammation, Linköping University.

Affiliated group members

Senait Ashenafi Betemariam

MD, PhD
H7 Department of Medicine, Huddinge
  • Sanait Ashenafi has a Medical Degree at Addis Ababa University (AAU), Ethiopia (1987).
  • Master of Science in Medical Biotechnology at Bergen University, Norway (1992).
  • Resident Physician in Pathology, "ST-läkare" at AAU, Ethiopia (1997).
  • PhD in Infection and Immunology at Karolinska Institutet (2013).
  • Postdoc in Infection and Immunology at Karolinska Institutet (2014-2015).
  • Assistant professor at Karolinska Institutet (2016-2019),
  • Associate professor at AAU, Ethiopia from 2019.

Jan Andersson

Professor, Head of Research and Development, Stockholm County Council
H7 Department of Medicine, Huddinge
  • Jan Andersson has a Medical Degree at Karolinska Institutet (1978).
  • Resident Physician in Infectious Diseases, "ST-läkare" at Danderyd Hospital (1982).
  • PhD in Infection and Immunology at Karolinska Institutet and Danderyd Hospital (1985).
  • Postdoc in Infection and Immunology at the DNAX research Institute, CA, USA (1987) and North Western University Medical School, Chicago, USA (1988).
  • Associate professor in Infectious Diseases at KI (1996).
  • Professor in Infectious Diseases at KI (1998).
  • Vice President at KI (2010-2012), Head of Research and Development, Stockholm County Council from 2013.

Open positions

We always want to get in touch with talented potential co-workers. If you are interested in doing research within our group, as a degree project or as a researcher, please contact the group leader Susanna Brighenti.

Previous group members

Jagadees Rao Muvva, PhD student.Thesis work at KI: "Studies of effector functions in Mycobacterium tuberculosis-infected macrophages with implications for host-directed therapies" (2013-2019).

Nebiat Gebreselassie, postdoc (2012-2015)

Pablo Giusti, postdoc (2012-2014)

Jubayer Rahman, postdoc (2010-2012)

Anders Rehn, postdoc (2008-2010)

Senait Ashenafi, PhD student, postdoc and Assistant professor Thesis work at KI: "Studies of dysfunctional cellular immunity in human tuberculosis disease with implications for immune reconstitution" (2007-2013).

Sayma Rahman, PhD student. Thesis work at KI: "Local immune responses in tuberculosis: Cytolytic effector functions at the site of Mycobacterium tuberculosis infection" (2007-2013).

Arina Samarina, Licentiate student. Thesis work at KI: "Cell mediated immune responses in tissue from patients with pulmonary tuberculosis" (2003-2005).

Key collaborations

The IRETB (Immune Reconsitution in TB disease) project team in Addis Ababa, Ethiopia. From top left: Dr. Wondwossen Amogne, Dr. Amsalu Bekele, Prof. Getachew Aderaye, Dr. Senait Ashenafi and Dr. Endale Kassa (Dept. of Internal Medicine, Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia). From lower left: Dr. Nebiat Gebreselassie, Armauer Hansen Research Institute (AHRI, Addis Ababa, Ethiopia), Prof. Getachew Aseffa (Dept. of Radiology, Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia), Prof. Jan Andersson and Dr. Susanna Brighenti, MedH, KI.

Karolinska Institutet

Karolinska Institutet, Department of Laboratory Medicine (Labmed): 
Assoc. Prof. Peter Bergman and Prof. Birgitta Agerberth.

Sweden

Linköping University, Department of Clinical and Experimental Medicine:
Prof. Maria Lerm and Assoc. prof. Thomas Schön

Public Health Agency of Sweden (PHAS):
Dr. Ramona Groenheit and Dr. Melles Haile

International

Addis Ababa University (AAU) and Black Lion University Hospital, Ethiopia:
Dr. Amsalu Bekele, Dr. Wondwossen Amogne, Dr. Endale Kassa and Prof. Getachew Aderaye

Armauer Hansen Research Institute (AHRI), Ethiopia:
Assoc. prof. Abdissa Alemseged (Scientific Director of AHRI) and Prof. Abraham Aseffa

International Centre for Diarrhoeal Disease Research (icddrb), Bangladesh:
PhD Rubhana Raqib

University College London (UCL), UK:
Dr. Gabriele Pollara

Research support

  • The Swedish Heart- and Lung Foundation (HLF)
  • The Foundation to Prevent Antibiotic Resistance (Resist)
  • The Swedish Research Council (VR), (Medicine-Health and Development Research)
  • The Swedish International Development Cooperation Agency (SIDA)
  • The Swedish Civil Contingencies Agency (MSB)
  • The Swedish Society for Medical Research (SSMF)
  • Stiftelsen Clas Groschinskys Minnesfond
  • KI funding for doctoral education (KID)
  • KI funds

Selected publications

2019-2022

  1. High Glucose and Carbonyl Stress Impair HIF-1-Regulated Responses and the Control of Mycobacterium tuberculosis in Macrophages.
    Terán G, Li H, Catrina SB, Liu R, Brighenti S, Zheng X, Grünler J, Nylén S, Carow B, Rottenberg ME
    mBio 2022 Sep;():e0108622
     
  2. Anemia Is a Strong Predictor of Wasting, Disease Severity, and Progression, in Clinical Tuberculosis (TB).
    Ashenafi S, Bekele A, Aseffa G, Amogne W, Kassa E, Aderaye G, Worku A, Bergman P, Brighenti S Nutrients 2022 Aug;14(16):
     
  3. Immunosuppressive Features of the Microenvironment in Lymph Nodes Granulomas from Tuberculosis and HIV-Co-Infected Patients.
    Ashenafi S, Muvva JR, Mily A, Snäll J, Zewdie M, Chanyalew M, Rehn A, Rahman S, Aseffa G, Bekele A, Aderaye G, Lema B, Svensson M, Brighenti S
    Am J Pathol 2022 04;192(4):653-670
     
  4. Immunomodulatory Agents Combat Multidrug-Resistant Tuberculosis by Improving Antimicrobial Immunity.
    Rao Muvva J, Ahmed S, Rekha RS, Kalsum S, Groenheit R, Schön T, Agerberth B, Bergman P, Brighenti S
    J Infect Dis 2021 Jul;224(2):332-344
     
  5. Immunomodulatory Agents Combat Multidrug-Resistant Tuberculosis by Improving Antimicrobial Immunity.
    Rao Muvva J, Ahmed S, Rekha RS, Kalsum S, Groenheit R, Schön T, Agerberth B, Bergman P, Brighenti S.
    J Infect Dis. 2021 Jul 15;224(2):332-344.
     
  6. Slow radiological improvement and persistent low-grade inflammation after chemotherapy in tuberculosis patients with type 2 diabetes.
    Mily A, Sarker P, Taznin I, Hossain D, Haq MA, Kamal SMM, et al. BMC Infect Dis 2020 Dec;20(1):933
     
  7. Polarization of M1 and M2 Human Monocyte-Derived Cells and Analysis with Flow Cytometry upon Mycobacterium tuberculosis Infection.
    Mily A, Kalsum S, Loreti MG, Rekha RS, Muvva JR, Lourda M, et al.J Vis Exp 2020 09;(163):
     
  8. Host and Pathogen Communication in the Respiratory Tract: Mechanisms and Models of a Complex Signaling Microenvironment.
    Berry SB, Haack AJ, Theberge AB, Brighenti S, Svensson M. Front Med (Lausanne) 2020 ;7():537
     
  9. Targeted Nutrition in Chronic Disease.
    Bergman P, Brighenti S. Nutrients 2020 Jun;12(6):
     
  10. Polarization of Human Monocyte-Derived Cells With Vitamin D Promotes Control of Mycobacterium tuberculosis Infection.
    Rao Muvva J, Parasa VR, Lerm M, Svensson M, Brighenti S. Front Immunol 2019 ;10():3157
     
  11. Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1.
    Missailidis C, Sørensen N, Ashenafi S, Amogne W, Kassa E, Bekele A, et al. Nutrients 2019 Jul;11(7):
     
  12. Daily Nutritional Supplementation with Vitamin D₃ and Phenylbutyrate to Treatment-Naïve HIV Patients Tested in a Randomized Placebo-Controlled Trial.
    Ashenafi S, Amogne W, Kassa E, Gebreselassie N, Bekele A, Aseffa G, et al. Nutrients 2019 Jan;11(1):
SB
Content owner:
Susanna Brighenti
25-10-2022